Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The study aims to assess the safety and tolerability of subcutaneous Ig NextGen 16% in
patients with Primary Immune Deficiency who require Immunoglobulin (Ig) G replacement
therapy. Ig NextGen 16% is a liquid immunoglobulin (antibody) preparation.
Phase:
Phase 3
Details
Lead Sponsor:
CSL Limited
Treatments:
Antibodies Immunoglobulin G Immunoglobulins Immunoglobulins, Intravenous